A new medicine has proven promising to combat Parkinson’s disease while minimizing unwanted side effects.
It was discovered that the pill once a day, Tavapadon, relieves rigidity, stiffness, coordination, tremors and movement, for a longer period of time for patients who also less than 400 mg of Levodopa per day and were experiments “Medication USA off and Sytoms Return, according to the study.
Until now, Levodopa has been the standard first -line treatment for Parkinson’s patients.
Parkinson’s cases could be doubled worldwide by 2050, the study reveals
Levodopa, which becomes dopamine in the brain and addresses dopamine receptors D2/d4/d4, has related to side effects that include sleep disorders, hallucinations, impulse control behavior disorders, weight gain, swelling and blood pressure.
A new medicine has proven promising to combat Parkinson’s disease while minimizing unwanted side effects. (Istock)
In the study, it was discovered that Tavapadon, which works imitating dopamine and aimed at D1/D5 receptors, had the same as Levodopa without the announcement, according to Hubert H. Fernández, MD, ATOR and director of the center of the center.
The dance facilitates the symptoms of depression in Parkinson’s patients, suggests a new study
“It provides patients with another option to relieve their motor fluctuations that are commonly experienced with Levodopa (the best medication we have so far in Parkinson) in moderate to advanced internships from the disorder,” Fernández told Fox News Digital.
“This global, multiple and fundamental fundamental trial showed that patients placed in Tavapadon had significantly more ‘in time’ and less” discount time “compared to those who received placebo and that the medicine was well tolerated by patients.”
Tavapadon is a pill once a day, while the current first -line medication, Levodopa, requires three pills daily. (Istock)
In the study, the researchers measured the disorders of the patient impulse control, excessive diurnal drowsiness, changes in blood pressure and weight changes, and discovered that the advertising effects linked to Tavapadon were not different from those who received a Pacobo.
“Or, of course, this is a short -term study, and we must wait for our long -term study to be really sure that our preliminary observations are still true,” said Fernández. “However, we are very encouraged.”
“Regardless of when used, either in the beginning or as a complementary therapy for Levodopa, we believe it is a general gain.”
The researchers presented the results of the tempo 3 essay at the American Academy of Neurology (AAN) earlier this month in San Diego.
For those who were recently diagnosed and have less severe motor symptoms, Fernández suggested that a dose or tavapadon once a day could potentially replace the levodopa dose three times a day.
“It provides patients with another option to relieve their motor fluctuations that are commonly experimental with Levodopa (the best medication we have so far in Parkinson) in the moderate stages of the disorder,” said a researcher. (Istock)
“If they require Levodopa at some point, they will need a LOER and less frequency dose, which reduces their probability of motor development and discline as side effects and other side effects,” he said in a press release.
For those with more advanced Parkinson, Tavapadon could match Levodopa.
Amid the Parkinson’s diagnosis of Brett Favre, the neurologist analyzes how the risk of brain shocks impact
“Then, regardless of when used, either in the beginning or as a therapy attached to the Levodopa, we believe it is a general gain,” Fernández added.
Recent research has found that Parkinson’s cases are expected to increase by 2050, which affect up to 25 million people worldwide.
The greatest increase will affect aged people 80 years or moreWith cases in that age group that are projected to increase by 196% by 2050, they noticed.
Among people over 80, it is projected that Parkinson’s cases will increase by 196% by 2050. (Istock)
As the results of the long -term trial are pending, ABBVIE, the Tavapadon manufacturer, will soon submit a request to the Food and Medicines Administration for the Medication Focus.
“The FDA will review the application: from there, they can address it for use, ask more questions that may not be clear or request another study or an extension to verify some results,” said Fernández.
Click here to get the Fox News application
“We hope that this new generation of dopamine agonist, which will be more selective in its stimulation of the dopamine receptor, and that only our newspaper lasts, will be a significant improvement in the symptomatic treatment of the symptoms of EP in the early and advanced base.” ”
Click here to register in our health newsletter
Dr. Mary Ann Picone, medical director of the MS Center in Holy Name Medical Center in Teaneck, New Jersey, did not participate in the study, but described the results as “very interesting and encouraging as a new tool to improve the quality of life of Parkinson’s disease.”
Recent research has found that Parkinson’s cases are expected to increase by 2050, which affect up to 25 million people worldwide.
“One of the main limitations of long -term use of dopamine is wear phenomena and the need to dose it more frequently,” Picone told Fox News Digital.
“The use of dopamine agonists helps prolong the long -term benefit of dopamine. The decreased benefit of dopamine can lead to” freezing “or episodes where patients have stiffness and difficulty moving.”
For more health articles, visit www.foxnews.com/health
“This new therapy would go to different receptors and allow more ‘on’ time, but without involuntary dyskinesia (not controlled movements) that … can interfere with the function.”
